🚀 VC round data is live in beta, check it out!
Boston Scientific Valuation Multiples
Discover revenue and EBITDA valuation multiples for Boston Scientific and similar public comparables like Medtronic, Danaher, Stryker, Siemens Healthineers and more.
Boston Scientific Overview
About Boston Scientific
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, kidney stone management, cardiac rhythm management, catheter-directed ultrasound imaging, upper gastrointestinal tract diagnostics, interventional oncology, neuromodulation for chronic pain, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for roughly 36% of the firm's total sales.
Founded
1979
HQ
Employees
59.0K
Website
Financials (LTM)
EV
$123B
Boston Scientific Financials
Boston Scientific reported last 12-month revenue of $21B and EBITDA of $6B.
In the same LTM period, Boston Scientific generated $14B in gross profit, $6B in EBITDA, and $5B in net income.
Revenue (LTM)
Boston Scientific P&L
In the most recent fiscal year, Boston Scientific reported revenue of $20B and EBITDA of $6B.
Boston Scientific expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $21B | XXX | $20B | XXX | XXX | XXX |
| Gross Profit | $14B | XXX | $14B | XXX | XXX | XXX |
| Gross Margin | 70% | XXX | 69% | XXX | XXX | XXX |
| EBITDA | $6B | XXX | $6B | XXX | XXX | XXX |
| EBITDA Margin | 32% | XXX | 31% | XXX | XXX | XXX |
| EBIT Margin | 28% | XXX | 28% | XXX | XXX | XXX |
| Net Profit | $5B | XXX | $5B | XXX | XXX | XXX |
| Net Margin | 23% | XXX | 23% | XXX | XXX | XXX |
| Net Debt | — | — | $9B | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Boston Scientific Stock Performance
Boston Scientific has current market cap of $113B, and enterprise value of $123B.
Market Cap Evolution
Boston Scientific's stock price is $76.22.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $123B | $113B | 0.0% | XXX | XXX | XXX | $3.08 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialBoston Scientific Valuation Multiples
Boston Scientific trades at 6.0x EV/Revenue multiple, and 18.9x EV/EBITDA.
EV / Revenue (LTM)
Boston Scientific Financial Valuation Multiples
As of March 23, 2026, Boston Scientific has market cap of $113B and EV of $123B.
Equity research analysts estimate Boston Scientific's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Boston Scientific has a P/E ratio of 24.0x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $113B | XXX | $113B | XXX | XXX | XXX |
| EV (current) | $123B | XXX | $123B | XXX | XXX | XXX |
| EV/Revenue | 6.0x | XXX | 6.1x | XXX | XXX | XXX |
| EV/EBITDA | 18.9x | XXX | 19.4x | XXX | XXX | XXX |
| EV/EBIT | 21.2x | XXX | 21.8x | XXX | XXX | XXX |
| EV/Gross Profit | 8.5x | XXX | 8.8x | XXX | XXX | XXX |
| P/E | 24.0x | XXX | 24.7x | XXX | XXX | XXX |
| EV/FCF | 33.3x | XXX | 33.5x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Boston Scientific Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Boston Scientific Margins & Growth Rates
Boston Scientific's revenue in the last 12 month grew by 11%.
Boston Scientific's revenue per employee in the last FY averaged $0.3M.
Boston Scientific's rule of 40 is 42% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Boston Scientific's rule of X is 59% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Boston Scientific Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 11% | XXX | 11% | XXX | XXX | XXX |
| EBITDA Margin | 32% | XXX | 31% | XXX | XXX | XXX |
| EBITDA Growth | 12% | XXX | 12% | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 42% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 59% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.3M | XXX | XXX | XXX |
| S&M Expenses to Revenue | 34% | XXX | — | XXX | XXX | XXX |
| R&D Expenses to Revenue | 10% | XXX | 10% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 49% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Boston Scientific Public Comps
See public comps and valuation multiples for other Medical Devices comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Medtronic | XXX | XXX | XXX | XXX | XXX | XXX |
| Danaher | XXX | XXX | XXX | XXX | XXX | XXX |
| Stryker | XXX | XXX | XXX | XXX | XXX | XXX |
| Siemens Healthineers | XXX | XXX | XXX | XXX | XXX | XXX |
| IDEXX Laboratories | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Boston Scientific M&A Activity
Boston Scientific acquired XXX companies to date.
Last acquisition by Boston Scientific was on XXXXXXXX, XXXXX. Boston Scientific acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Boston Scientific
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialBoston Scientific Investment Activity
Boston Scientific invested in XXX companies to date.
Boston Scientific made its latest investment on XXXXXXXX, XXXXX. Boston Scientific invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Boston Scientific
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Boston Scientific
| When was Boston Scientific founded? | Boston Scientific was founded in 1979. |
| Where is Boston Scientific headquartered? | Boston Scientific is headquartered in United States. |
| How many employees does Boston Scientific have? | As of today, Boston Scientific has over 59K employees. |
| Who is the CEO of Boston Scientific? | Boston Scientific's CEO is Michael F. Mahoney. |
| Is Boston Scientific publicly listed? | Yes, Boston Scientific is a public company listed on NYSE. |
| What is the stock symbol of Boston Scientific? | Boston Scientific trades under BSX ticker. |
| When did Boston Scientific go public? | Boston Scientific went public in 1992. |
| Who are competitors of Boston Scientific? | Boston Scientific main competitors are Medtronic, Danaher, Stryker, Siemens Healthineers. |
| What is the current market cap of Boston Scientific? | Boston Scientific's current market cap is $113B. |
| What is the current revenue of Boston Scientific? | Boston Scientific's last 12 months revenue is $21B. |
| What is the current revenue growth of Boston Scientific? | Boston Scientific revenue growth (NTM/LTM) is 11%. |
| What is the current EV/Revenue multiple of Boston Scientific? | Current revenue multiple of Boston Scientific is 6.0x. |
| Is Boston Scientific profitable? | Yes, Boston Scientific is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Boston Scientific? | Boston Scientific's last 12 months EBITDA is $6B. |
| What is Boston Scientific's EBITDA margin? | Boston Scientific's last 12 months EBITDA margin is 32%. |
| What is the current EV/EBITDA multiple of Boston Scientific? | Current EBITDA multiple of Boston Scientific is 18.9x. |
| What is the current FCF of Boston Scientific? | Boston Scientific's last 12 months FCF is $4B. |
| What is Boston Scientific's FCF margin? | Boston Scientific's last 12 months FCF margin is 18%. |
| What is the current EV/FCF multiple of Boston Scientific? | Current FCF multiple of Boston Scientific is 33.3x. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.